ReviewJournal of neuro-oncology2024
Understanding current experimental models of glioblastoma-brain microenvironment interactions.
Review in Journal of neuro-oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 14 citations in OpenAlex.
- Mimicking tumor hypoxia in a glioblastoma-on-a-chip.Materials today. Bio · 2026Article
- Human Blood-Brain Tumor Barrier on a Chip to Investigate Personalized Treatment for Glioblastoma Patients.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Patient-derived glioblastoma cultures preserve respiration phenotypes during ex vivo maintenance and show sex-associated differences in migration.Acta neuropathologica communications · 2026Article
- Overexpression of miR-219 as a potential therapeutic strategy of glioblastoma cells in vitro.Scientific reports · 2026Article
- Triple-Survival Stereotactic Brain Surgeries for the Intracranial Injections of Glioblastoma Stem-like Cells and Oncolytic Herpes Simplex Viruses.Methods and protocols · 2026Article
- A brain-penetrant chimeric protein combines direct glioma targeting with myeloid cell-mediated immune reprogramming.Journal of translational medicine · 2026Article
- Organoids to Model Tumor Microenvironment in Progression of Pathogenesis and Treatment Resistance in Glioblastoma Multiforme.Brain sciences · 2026Review
- Dissecting acute neuronal responses to glioblastoma using a dual-interface human iPSC neuronal culture platform.Acta neuropathologica communications · 2026Article
- Integrated 2D-3D Proteomic Profiling Identifies MLK4 as a Microenvironment-Responsive Regulator of Chemotherapeutic Resistance in Human Glioblastoma Cells.Biology of the cell · 2026Article
- C5aR1 Inhibition Alleviates Cranial Radiation-Induced Cognitive Decline.Cancer research · 2026Article
- Pathological neural and immune synapses in glioblastoma progression: mechanisms and therapeutic opportunities.Frontiers in neural circuits · 2026Review
- Advancing glioblastoma research by establishing a whole brain slice model.Frontiers in oncology · 2026Article
- A Novel Serum-Free Triculture Model of Glioblastoma, Astrocytes, and Macrophages.International journal of molecular sciences · 2025Article
- Synergistic activity of simvastatin and irinotecan chemotherapy against glioblastoma converges on TGF-β signaling.Journal of neuro-oncology · 2025Article
- Role of Coiled-Coil Domain-Containing Protein 86 in Tumorigenesis of Nasopharyngeal Carcinoma.Bulletin of experimental biology and medicine · 2025Article
- Three-dimensional regulatory hubs support oncogenic programs in glioblastoma.Molecular cell · 2025Article
- Review
- Three-dimensional regulatory hubs support oncogenic programs in glioblastoma.bioRxiv : the preprint server for biology · 2024Article
- About the incompleteness of our models.Journal of neuro-oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Glioblastoma (GBM) is a common and devastating primary brain tumor, with median survival of 16-18 months after diagnosis in the setting of substantial resistance to standard-of-care and inevitable tumor recurrence. Recent work has implicated the brain microenvironment as being critical for GBM proliferation, invasion, and resistance to treatment. GBM does not operate in isolation, with neurons, astrocytes, and multiple immune populations being implicated in GBM tumor progression and invasiveness. The goal of this review article is to provide an overview of the available in vitro, ex vivo, and in vivo experimental models for assessing GBM-brain interactions, as well as discuss each model's relative strengths and limitations. Current in vitro models discussed will include 2D and 3D co-culture platforms with various cells of the brain microenvironment, as well as spheroids, whole organoids, and models of fluid dynamics, such as interstitial flow. An overview of in vitro and ex vivo organotypic GBM brain slices is also provided. Finally, we conclude with a discussion of the various in vivo rodent models of GBM, including xenografts, syngeneic grafts, and genetically-engineered models of GBM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.